Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Kapur, S. Articles by Remington, G. Search for Related Content PubMed Citation Articles by Kapur, S. Articles by Remington, G. Neurotransmitters Schizophrenia Spectrum Disorders Other Neuroleptics PET

Clinical and Theoretical Implications of 5-HT₂ and D₂ Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia

OBJECTIVE: Dopamine D₂ receptor occupancy measurements provide a valid predictor of antipsychotic response, extrapyramidal side effects, and elevation of prolactin levels. The new antipsychotics clozapine, risperidone, and olanzapine obtain antipsychotic response with few extrapyramidal side effects and little prolactin elevation. The purpose of this study was to compare the D₂ and serotonin 5-HT₂ receptor occupancies of these drugs in patients receiving multiple-dose, steady-state regimens. METHOD: Forty-four patients with schizophrenia (16 taking risperidone, 2–12 mg/day; 17 taking olanzapine, 5–60 mg/day; and 11 taking clozapine, 75–900 mg/day) had their D₂ and 5-HT₂ occupancies determined with the use of [¹¹C]raclopride and [¹⁸F]setoperone, respectively, and positron emission tomography imaging. RESULTS: Clozapine showed a much lower D₂ occupancy (16%–68%) than risperidone (63%–89%) and olanzapine (43%–89%). Risperidone and olanzapine gave equal D₂ occupancies at doses of 5 and 20 mg/day, respectively. All three drugs showed greater 5-HT₂ than D₂ occupancy at all doses, although the difference was greatest for clozapine. CONCLUSIONS: Clozapine, at doses known to be effective in routine clinical settings, showed a D₂ occupancy clearly lower than that of typical antipsychotics, while risperidone and olanzapine at their usual clinical doses gave the same level of D₂ occupancy as low-dose typical antipsychotics. The results also suggest that some previous clinical comparisons of antipsychotics may have been confounded by different levels of D₂ occupancy. Clinical comparisons of these drugs, matching for D₂ occupancy, may provide a better measure of their true "atypicality" and will help in understanding the contribution of non-D₂ receptors to antipsychotic effects.

This article has been cited by other articles:

				C. Dolder, M. Nelson, and Z. Deyo Paliperidone for schizophrenia Am. J. Health Syst. Pharm., March 1, 2008; 65(5): 403 - 413. [Abstract] [Full Text] [PDF]

				J. M. Stone, J. M. Davis, S. Leucht, and L. S. Pilowsky Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature Schizophr Bull, February 26, 2008; (2008) sbn009v1. [Abstract] [Full Text] [PDF]

				H. D. Burns, K. Van Laere, S. Sanabria-Bohorquez, T. G. Hamill, G. Bormans, W.-s. Eng, R. Gibson, C. Ryan, B. Connolly, S. Patel, et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor PNAS, June 5, 2007; 104(23): 9800 - 9805. [Abstract] [Full Text] [PDF]

				G. Remington, D. Mamo, A. Labelle, J. Reiss, C. Shammi, E. Mannaert, S. Mann, and S. Kapur A PET Study Evaluating Dopamine D2 Receptor Occupancy for Long-Acting Injectable Risperidone Am J Psychiatry, March 1, 2006; 163(3): 396 - 401. [Abstract] [Full Text] [PDF]

				W. G. Honer, A. E. Thornton, E. Y.H. Chen, R. C.K. Chan, J. O.Y. Wong, A. Bergmann, P. Falkai, E. Pomarol-Clotet, P. J. McKenna, E. Stip, et al. Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia N. Engl. J. Med., February 2, 2006; 354(5): 472 - 482. [Abstract] [Full Text] [PDF]

				K. Rasmussen, M. J. Benvenga, F. P. Bymaster, D. O. Calligaro, I. R. Cohen, J. F. Falcone, S. K. Hemrick-Luecke, F. M. Martin, N. A. Moore, L. K. Nisenbaum, et al. Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: A Potential Novel Antipsychotic with Lower Histamine H1 Receptor Affinity Than Olanzapine J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1265 - 1277. [Abstract] [Full Text] [PDF]

				J. Woolley and P. McGuire Neuroimaging in schizophrenia: what does it tell the clinician? Advan. Psychiatr. Treat., May 1, 2005; 11(3): 195 - 202. [Abstract] [Full Text] [PDF]

				D. J. Lang, L. C. Kopala, R. A. Vandorpe, Q. Rui, G. N. Smith, V. M. Goghari, J. S. Lapointe, and W. G. Honer Reduced Basal Ganglia Volumes After Switching to Olanzapine in Chronically Treated Patients With Schizophrenia Am J Psychiatry, October 1, 2004; 161(10): 1829 - 1836. [Abstract] [Full Text] [PDF]

				R. A. Bantick, A. J. Montgomery, C. J. Bench, T. Choudhry, N. Malek, P. J. McKenna, D. J. Quested, J. F. W. Deakin, and P. M. Grasby A Positron Emission Tomography Study of the 5-Ht1A Receptor in Schizophrenia and during Clozapine Treatment J Psychopharmacol, September 1, 2004; 18(3): 346 - 354. [Abstract] [PDF]

				R. M. Moresco, R. Cavallaro, C. Messa, D. Bravi, C. Gobbo, L. Galli, G. Lucignani, C. Colombo, G. Rizzo, I. Velona, et al. Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or Clozapine J Psychopharmacol, September 1, 2004; 18(3): 355 - 365. [Abstract] [PDF]

				K. Meguro, M. Meguro, Y. Tanaka, K. Akanuma, K. Yamaguchi, and M. Itoh Risperidone is Effective for Wandering and Disturbed Sleep/Wake Patterns in Alzheimer's Disease J Geriatr Psychiatry Neurol, June 1, 2004; 17(2): 61 - 67. [Abstract] [PDF]

				D. Mamo, S. Kapur, C. M. Shammi, G. Papatheodorou, S. Mann, F. Therrien, and G. Remington A PET Study of Dopamine D2 and Serotonin 5-HT2 Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone Am J Psychiatry, May 1, 2004; 161(5): 818 - 825. [Abstract] [Full Text] [PDF]

				R. A. Bressan, H. M. Jones, and L. S. Pilowsky Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity J Psychopharmacol, March 1, 2004; 18(1): 124 - 127. [Abstract] [PDF]

				F. Paquet, J. P. Soucy, E. Stip, M. Levesque, A. Elie, and M. A. Bedard Comparison Between Olanzapine and Haloperidol on Procedural Learning and the Relationship With Striatal D2 Receptor Occupancy in Schizophrenia J Neuropsychiatry Clin Neurosci, February 1, 2004; 16(1): 47 - 56. [Abstract] [Full Text] [PDF]

				H. Takahashi, T. Sugita, K. Yoshida, H. Higuchi, and T. Shimizu Effect of Quetiapine in the Treatment of Panic Attacks in Patients with Schizophrenia: 3 Case Reports J Neuropsychiatry Clin Neurosci, February 1, 2004; 16(1): 113 - 115. [Abstract] [Full Text] [PDF]

				P. Seeman Atypical Antipsychotics: Mechanism of Action Focus, January 1, 2004; 2(1): 48 - 58. [Abstract] [Full Text] [PDF]

				G. Grunder, A. Carlsson, and D. F. Wong Mechanism of New Antipsychotic Medications: Occupancy Is Not Just Antagonism Arch Gen Psychiatry, October 1, 2003; 60(10): 974 - 977. [Abstract] [Full Text] [PDF]

				C. Arango, A. Breier, R. McMahon, W. T. Carpenter Jr., and R. W. Buchanan The Relationship of Clozapine and Haloperidol Treatment Response to Prefrontal, Hippocampal, and Caudate Brain Volumes Am J Psychiatry, August 1, 2003; 160(8): 1421 - 1427. [Abstract] [Full Text] [PDF]

				S. Kapur, S. C. VanderSpek, B. A. Brownlee, and J. N. Nobrega Antipsychotic Dosing in Preclinical Models Is Often Unrepresentative of the Clinical Condition: A Suggested Solution Based on in Vivo Occupancy J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 625 - 631. [Abstract] [Full Text] [PDF]

				B. Alevizos, C. Papageorgiou, and G. N. Christodoulou Acute Dystonia Caused by Low Dosage of Olanzapine J Neuropsychiatry Clin Neurosci, May 1, 2003; 15(2): 241 - 241. [Full Text] [PDF]

				L. de Haan, M. van Bruggen, J. Lavalaye, J. Booij, P. M.A.J. Dingemans, and D. Linszen Subjective Experience and D2 Receptor Occupancy in Patients With Recent-Onset Schizophrenia Treated With Low-Dose Olanzapine or Haloperidol: A Randomized, Double-Blind Study Am J Psychiatry, February 1, 2003; 160(2): 303 - 309. [Abstract] [Full Text] [PDF]

				W. Sun, N. Ginovart, F. Ko, P. Seeman, and S. Kapur In Vivo Evidence for Dopamine-Mediated Internalization of D2-Receptors after Amphetamine: Differential Findings with [3H]Raclopride versus [3H]Spiperone Mol. Pharmacol., February 1, 2003; 63(2): 456 - 462. [Abstract] [Full Text] [PDF]

				S. Ahmed, P. D. Mozley, and W. Z. Potter Biomarkers in Psychotropic Drug Development Am J Geriatr Psychiatry, December 1, 2002; 10(6): 678 - 686. [Abstract] [Full Text] [PDF]

				H. M. JONES and L. S. PILOWSKY Dopamine and antipsychotic drug action revisited The British Journal of Psychiatry, October 1, 2002; 181(4): 271 - 275. [Full Text] [PDF]

				A E Hensiek and M R Trimble Relevance of new psychotropic drugs for the neurologist J. Neurol. Neurosurg. Psychiatry, March 1, 2002; 72(3): 281 - 285. [Full Text] [PDF]

				R. R. Conley and R. Mahmoud A Randomized Double-Blind Study of Risperidone and Olanzapine in the Treatment of Schizophrenia or Schizoaffective Disorder Am J Psychiatry, May 1, 2001; 158(5): 765 - 774. [Abstract] [Full Text]

				F. I. Tarazi, K. Zhang, and R. J. Baldessarini Long-Term Effects of Olanzapine, Risperidone, and Quetiapine on Dopamine Receptor Types in Regions of Rat Brain: Implications for Antipsychotic Drug Treatment J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 711 - 717. [Abstract] [Full Text]

				D. J. Lang, L. C. Kopala, R. A. Vandorpe, Q. Rui, G. N. Smith, V. M. Goghari, and W. G. Honer An MRI Study of Basal Ganglia Volumes in First-Episode Schizophrenia Patients Treated With Risperidone Am J Psychiatry, April 1, 2001; 158(4): 625 - 631. [Abstract] [Full Text]

				S. Kapur and P. Seeman Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis Am J Psychiatry, March 1, 2001; 158(3): 360 - 369. [Abstract] [Full Text]

				P. G. Strange Antipsychotic Drugs: Importance of Dopamine Receptors for Mechanisms of Therapeutic Actions and Side Effects Pharmacol. Rev., March 1, 2001; 53(1): 119 - 134. [Abstract] [Full Text] [PDF]

				S. Kapur, P. Roy, J. Daskalakis, G. Remington, and R. Zipursky Increased Dopamine D2 Receptor Occupancy and Elevated Prolactin Level Associated With Addition of Haloperidol to Clozapine Am J Psychiatry, February 1, 2001; 158(2): 311 - 314. [Abstract] [Full Text]

				D. Mossman and D. S. Lehrer Conventional and Atypical Antipsychotics and the Evolving Standard of Care Psychiatr Serv, December 1, 2000; 51(12): 1528 - 1535. [Abstract] [Full Text] [PDF]

				C. G. Goetz, L. M. Blasucci, S. Leurgans, and E. J. Pappert Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients Neurology, September 26, 2000; 55(6): 789 - 794. [Abstract] [Full Text] [PDF]

				A. J. Manson, A. Schrag, and A. J. Lees Low-dose olanzapine for levodopa induced dyskinesias Neurology, September 26, 2000; 55(6): 795 - 799. [Abstract] [Full Text] [PDF]

				P. Seeman and S. Kapur Schizophrenia: More dopamine, more D2 receptors PNAS, July 5, 2000; 97(14): 7673 - 7675. [Full Text] [PDF]

				L. de Haan, J. Lavalaye, D. Linszen, P. M.A.J. Dingemans, and J. Booij Subjective Experience and Striatal Dopamine D2 Receptor Occupancy in Patients With Schizophrenia Stabilized by Olanzapine or Risperidone Am J Psychiatry, June 1, 2000; 157(6): 1019 - 1020. [Abstract] [Full Text]

				S. Kapur, R. Zipursky, C. Jones, C. S. Shammi, G. Remington, and P. Seeman A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy Arch Gen Psychiatry, June 1, 2000; 57(6): 553 - 559. [Abstract] [Full Text] [PDF]

				G. E. Duncan, S. Miyamoto, J. N. Leipzig, and J. A. Lieberman Comparison of the Effects of Clozapine, Risperidone, and Olanzapine on Ketamine-Induced Alterations in Regional Brain Metabolism J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 8 - 14. [Abstract] [Full Text]

				S. Kapur, R. Zipursky, C. Jones, G. Remington, and S. Houle Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia Am J Psychiatry, April 1, 2000; 157(4): 514 - 520. [Abstract] [Full Text]

				P. Seeman and T. Tallerico Rapid Release of Antipsychotic Drugs From Dopamine D2 Receptors: An Explanation for Low Receptor Occupancy and Early Clinical Relapse Upon Withdrawal of Clozapine or Quetiapine Am J Psychiatry, June 1, 1999; 156(6): 876 - 884. [Abstract] [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 1999 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us